ImpediMed Stock

ImpediMed ROE

The Return on Equity (ROE) of ImpediMed (IPD.AX) as of Aug 5, 2026 is -113.37 %. In the previous year, Return on Equity (ROE) was -48.57 % — a change of 133.41% (lower).

ROE

-113.37 %

YoY

133.41%

Last updated:

In 2026, ImpediMed's return on equity (ROE) was -113.37 %, a 133.41% increase from the -48.57 % ROE in the previous year.

Access this data via the Eulerpool API

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

ROE Details

Decoding ImpediMed's Return on Equity (ROE)

ImpediMed's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing ImpediMed's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

ImpediMed's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in ImpediMed’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about ImpediMed stock

Return on Equity (ROE) of ImpediMed is -113.37 % in 2026.

Return on Equity (ROE) of ImpediMed changed from -48.57 % to -113.37 %, representing a 133.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) ImpediMed since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s ImpediMed with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — ImpediMed

All Key Metrics — ImpediMed